

Cell Line	Drug Combination	Cell Viability		Apoptosis	
		Observed	Predicted	Observed	Predicted
MOLT4	Ida + VPA 0.25 mM	.48	.27	.20	.18
MOLT4	Ida + VPA 1 mM	.53	.49	.29	.24
MOLT4	Ida + VPA 1.5 mM	.67	.57	ND	
MOLT4	Ida + VPA 3 Mm	.95	.85	.82	.72
MOLT4	Ida + Vor 0.075 $\mu$ M	.31	.25	.13	.17
MOLT4	Ida + Vor 0.3 $\mu$ M	.54	.53	.40	.25
MOLT4	Ida + Vor 0.45 $\mu$ M	.95	.90	.89	.80
MOLT4	Ida + Vor 1 $\mu$ M	.97	.97	.92	.89
HL60	Ida + VPA 0.25 mM	.39	.28	.04	.07
HL60	Ida + VPA 1 mM	.53	.38	.04	.06
HL60	Ida + VPA 1.5 mM	.77	.41	ND	
HL60	Ida + VPA 3 Mm	.62	.56	.07	.07
HL60	Ida + Vor 0.075 $\mu$ M	.41	.28	.02	0.06
HL60	Ida + Vor 0.3 $\mu$ M	.51	.45	.05	0.1
HL60	Ida + Vor 0.45 $\mu$ M	.64	.59	.19	.23
HL60	Ida + Vor 1 $\mu$ M	.98	.97	.61	.53

Ida, idarubicin; VPA, valproic acid; Vor, vorinostat; ND, not done. Idarubicin was used at the cell specific IC<sub>10</sub>: 0.5 nM for MOLT4 and 1.5 nM for HL60. Using the fractional method of Webb<sup>13</sup>, a combination is considered unlikely to be antagonistic if the observed fractional inhibition is superior to the predicted.